Hi all,
I will try another link about info from the UK MDS Patient Support Group: Almost a fifth (18 percent) of patients suffering from myelodysplastic syndromes (MDS) could have lived for longer if they had been able to access treatments (for example Vidaza) that are currently not approved by NICE for treatment on the NHS.
http://www.pressemeldinger.no/read.asp?recno=80455
Kind regards
Birgitta-A